EGFR and non-small cell lung carcinoma: The most common adverse events were leukopenia, neutropenia, anemia, elevated AST and ALT, nausea, and thrombocytopenia, which were consistent with the side effect of the similar chemo-immunotherapy combination in NSCLC patients without driver mutations.40 Interestingly, combination of EGFR-TKIs and PD-1 blockade would result in high rate of interstitial pneumonitis in patients with EGFR-mutant advanced NSCLC.